Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the proportion of patients (ie, responders) achieving at least a 1-h reduction…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a novel once-daily COMT inhibitor,…Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the association of patients’ perception of Parkinson’s Disease (PD) symptoms improvement (as assessed by Patient Global Impression of Change, PGIC) could be…Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease
Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience
Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience
Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated Parkinson’s Disease (PD) patients that switched from entacapone (ENT) to opicapone (OPC) in the…Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients when starting opicapone (OPC) 50mg or entacapone (ENT). Background:…ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.